An overview of the utility of prasugrel hydrochloride as a treatment option for ischemic stroke
Expert Rev Neurother. 2023 Dec 30:1-6. doi: 10.1080/14737175.2023.2295420. Online ahead of print.ABSTRACTINTRODUCTION: Prasugrel, a potent P2Y12 receptor inhibitor, is not currently recommended in patients with stroke due to a higher rate of recurrent stroke. Prasugrel was associated with comparable efficacy to clopidogrel in reducing the risk of ischemic stroke in a recent phase III study.AREAS COVERED: The authors provide an overview of the potential role of prasugrel in the management of ischemic stroke. The authors searched PUBMED, MEDLINE, and clinicaltrials.org and recently presented trials at the conferences for cli...
Source: Expert Review of Neurotherapeutics - December 30, 2023 Category: Neurology Authors: Udaya S Tantry Sahib Singh Kevin P Bliden Paul A Gurbel William Ashley Source Type: research
